These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16110609)

  • 21. Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II.
    De Renzo A; Santoro LF; Notaro R; Pane F; Buonaiuto MR; Luciano L; Rotoli B
    Am J Hematol; 1999 Apr; 60(4):300-4. PubMed ID: 10203104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
    Giles GI; Sharma RP
    Med Chem; 2005 Jul; 1(4):383-94. PubMed ID: 16789895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
    Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
    Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.
    Lansiaux A; Laine W; Baldeyrou B; Mahieu C; Wattez N; Vezin H; Martinez FJ; Piñeyro A; Bailly C
    Chem Res Toxicol; 2001 Jan; 14(1):16-24. PubMed ID: 11170504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
    Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
    Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced disease and new drugs.
    Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
    Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
    [No Abstract]   [Full Text] [Related]  

  • 28. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
    Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
    Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase-I inhibitors in the management of colon cancer.
    Willson JK
    Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
    [No Abstract]   [Full Text] [Related]  

  • 31. New Agents in Clinical Oncology. 24 November 2006, London, UK.
    Martin S
    IDrugs; 2007 Feb; 10(2):99-101. PubMed ID: 17285459
    [No Abstract]   [Full Text] [Related]  

  • 32. Etoposide, topoisomerase II and cancer.
    Baldwin EL; Osheroff N
    Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):363-72. PubMed ID: 16101488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons).
    Jenkins JR
    Br J Radiol; 2008 Oct; 81 Spec No 1():S69-77. PubMed ID: 18820001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor p53 status and response to topoisomerase II inhibitors.
    Valkov NI; Sullivan DM
    Drug Resist Updat; 2003 Feb; 6(1):27-39. PubMed ID: 12654285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
    Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S
    Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of topoisomerase II by liriodenine.
    Woo SH; Reynolds MC; Sun NJ; Cassady JM; Snapka RM
    Biochem Pharmacol; 1997 Aug; 54(4):467-73. PubMed ID: 9313773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase I inhibitors: topotecan and irenotecan.
    Creemers GJ; Lund B; Verweij J
    Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
    [No Abstract]   [Full Text] [Related]  

  • 38. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
    Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
    DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
    Kim DK; Lee N
    Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.